First positive reimbursement decision worldwide for LYTENAVA™; First launch anticipated in H1 2025LYTENAVA™ is the first and only approved ...

Outlook Therapeutics (OTLK) announced that the National Institute for Health and Care Excellence, NICE, has recommended LYTENAVA, as an option ...

Outlook Therapeutics (NASDAQ:OTLK – Free Report) had its target price reduced by BTIG Research from $50.00 to $9.00 in a ...

Fintel reports that on December 2, 2024, Chardan Capital downgraded their outlook for Outlook Therapeutics (NasdaqCM:OTLK) from Buy to Neutral. Analyst Price Forecast Suggests 1,865.37% Upside As of ...

In the assessment of 12-month price targets, analysts unveil insights for Voyager Therapeutics, presenting an average target ...

Outlook Therapeutics (NASDAQ:OTLK – Get Free Report)‘s stock had its “buy” rating reaffirmed by HC Wainwright in a report ...

Fintel reports that on December 2, 2024, UBS downgraded their outlook for Applied Therapeutics (NasdaqGM:APLT) from Buy to ...

Outlook Therapeutics Inc. (NASDAQ:OTLK) revealed preliminary topline results of NORSE EIGHT, the second of two clinical ...

BTIG lowered the firm’s price target on Outlook Therapeutics (OTLK) to $9 from $50 and keeps a Buy rating on the shares. The ...

Shares of AT&T Inc. T rose sharply during Tuesday's session after the company updated its 2024 guidance, raising the bottom ...

Outlook Therapeutics (OTLK) stock plunges 81% after clinical trial failure for its wet AMD therapy, ONS-5010. Read more here.

On Friday, Outlook Therapeutics Inc (OTLK) stock saw a modest uptick, ending the day at $1.97 which represents a slight increase of $0.27 or 15.88% from the prior close of $1.7. The stock opened at $1 ...